Objective: Chronic migraine encephalalgia (CME) with concomitant temporomandibular disorder (TMD) is a serious illness with limited effective treatment options. This study explores the effectiveness of onabotulinumtoxinA (BtxA) as an adjunct therapeutic to TMJ arthroscopy in the relief of CME.
Methods: A retrospective cohort study of patients receiving TMJ arthroscopy, with or without BtxA injections for CME, was conducted. Variables assessed include pain using a visual analog scale (VAS), maximal incisal opening (MIO), muscle soreness, and headache frequency and duration.
Results: Sixty patients (44 BtxA, 16 Control), consisting of 56 (93.3%) females, met inclusion criteria. A significant reduction in pain is reported with patients receiving BtxA ( < 0.0001) on VAS as compared to Control group. BtxA treatment also significantly reduced headache frequency and duration ( < 0.05).
Conclusion: These results support the use of adjunctive BtxA treatment with arthroscopy for the treatment of CME in the context of TMD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/08869634.2022.2045114 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Composite microRNA-genetic risk score model links to migraine and implicates its pathogenesis.
Brain
January 2025
Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.
The neurobiological mechanisms driving the ictal-interictal fluctuations and the chronification of migraine remain elusive. We aimed to construct a composite genetic-microRNA model that could reflect the dynamic perturbations of the disease course and inform the pathogenesis of migraine. We prospectively recruited four groups of participants, including interictal episodic migraine (i.
View Article and Find Full Text PDFPharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review.
Headache
January 2025
Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.
Antibodies targeting either the calcitonin gene-related peptide (CGRP), such as galcanezumab, fremanezumab, and eptinezumab, or the receptor (erenumab) have been approved for the prevention of episodic and chronic migraine. Although widely used and generally effective, a proportion of patients discontinue treatment due to lack of efficacy. In both randomized controlled trials and observational studies, all anti-CGRP monoclonal antibodies (mAbs) have consistently demonstrated comparable efficacy and tolerability, suggesting a pharmacological class effect.
View Article and Find Full Text PDFMedication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation.
J Headache Pain
January 2025
Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, USA.
Background: Migraine progression, particularly from episodic to chronic migraine (CM), increases disease burden and healthcare costs. Understanding the new concept of "Medication Underuse Headache" should encourage the health care provider to consider early intervention with calcitonin gene-related peptide (CGRP) monoclonal antibodies. Galcanezumab given early in the course of the disease, may prevent migraine chronification and have a robust response, moreso than when initiated in later stages of migraine.
View Article and Find Full Text PDFMigraine among King Khaled University students; prevalence, determinants, and impact on academic life.
J Clin Neurosci
January 2025
Family and Community Medicine Department, College of Medicine, King Khalid University, Abha, Saudi Arabia.
Background: Migraine is a common primary headache disorder that significantly affects academic life and is often associated with stress, depression, anxiety, and irregular sleep patterns among university students. This study aimed to assess the prevalence of migraine among King Khalid University (KKU) students, identify its determinants, and evaluate the impact of migraine and other headaches on academic life and performance.
Methods: An analytical cross-sectional study was conducted among 732 students from Colleges of Medicine, Pharmacy, Engineering, and Computer science.
Impact of Fatty Acid Supplementation on Migraine Outcomes: A Systematic Review and Meta-analysis.
Nutr Rev
January 2025
Universidad Europea de Madrid, Department of Physiotherapy, Faculty of Medicine, Health and Sports, 28670 Villaviciosa de odón, Madrid, Spain.
Context: Migraines are a prevalent neurological condition that significantly impacts the quality of life. Although narrative reviews and clinical trials suggest the potential effects of fatty acid supplementation as a promising approach for migraine prophylaxis, the findings remain inconsistent.
Objective: The aim was to evaluate the efficacy of fatty acid supplementation on migraine clinical outcomes through a systematic review and meta-analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!